| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Peripheral Arterial Disease | 15 | 2019 | 471 | 3.75 | Why? |
| Secondary Prevention | 5 | 2018 | 762 | 1.57 | Why? |
| Platelet Aggregation Inhibitors | 10 | 2019 | 1671 | 1.49 | Why? |
| Blood Platelets | 6 | 2019 | 1704 | 1.35 | Why? |
| Myocardial Infarction | 15 | 2020 | 3361 | 1.33 | Why? |
| Platelet Activation | 4 | 2019 | 660 | 1.24 | Why? |
| Carotid Stenosis | 2 | 2018 | 207 | 1.08 | Why? |
| Thrombosis | 8 | 2021 | 7504 | 0.98 | Why? |
| Calgranulin B | 2 | 2018 | 144 | 0.83 | Why? |
| Platelet Aggregation | 2 | 2019 | 318 | 0.78 | Why? |
| Training Support | 1 | 2020 | 131 | 0.78 | Why? |
| Mean Platelet Volume | 1 | 2020 | 203 | 0.74 | Why? |
| Fibrinolytic Agents | 3 | 2018 | 1702 | 0.71 | Why? |
| Motivational Interviewing | 1 | 2018 | 55 | 0.68 | Why? |
| Directive Counseling | 1 | 2017 | 77 | 0.65 | Why? |
| Education, Medical, Graduate | 4 | 2020 | 2082 | 0.64 | Why? |
| Arsenic | 1 | 2017 | 85 | 0.63 | Why? |
| Perioperative Period | 1 | 2018 | 276 | 0.63 | Why? |
| von Willebrand Diseases | 1 | 2017 | 81 | 0.62 | Why? |
| Lupus Erythematosus, Systemic | 2 | 2018 | 1380 | 0.61 | Why? |
| Cardiovascular Diseases | 8 | 2019 | 11497 | 0.61 | Why? |
| Aspirin | 4 | 2019 | 1043 | 0.61 | Why? |
| Monocytes | 2 | 2019 | 2978 | 0.60 | Why? |
| Internship and Residency | 6 | 2020 | 4987 | 0.59 | Why? |
| Postoperative Hemorrhage | 1 | 2017 | 183 | 0.59 | Why? |
| Lower Extremity | 5 | 2019 | 593 | 0.59 | Why? |
| Peripheral Vascular Diseases | 1 | 2016 | 133 | 0.58 | Why? |
| Human Umbilical Vein Endothelial Cells | 1 | 2017 | 286 | 0.58 | Why? |
| Fruit | 1 | 2017 | 313 | 0.57 | Why? |
| Venous Thromboembolism | 5 | 2020 | 4273 | 0.56 | Why? |
| Thrombelastography | 1 | 2020 | 627 | 0.56 | Why? |
| Megakaryocytes | 1 | 2017 | 274 | 0.56 | Why? |
| Vegetables | 1 | 2017 | 340 | 0.55 | Why? |
| Anticoagulants | 10 | 2021 | 9563 | 0.55 | Why? |
| Fibrin Fibrinogen Degradation Products | 5 | 2021 | 5993 | 0.54 | Why? |
| Rivaroxaban | 4 | 2018 | 467 | 0.53 | Why? |
| Ankle Brachial Index | 3 | 2018 | 53 | 0.52 | Why? |
| Stroke | 10 | 2020 | 8839 | 0.52 | Why? |
| P-Selectin | 3 | 2020 | 224 | 0.49 | Why? |
| Risk Reduction Behavior | 2 | 2017 | 946 | 0.49 | Why? |
| Atherosclerosis | 2 | 2017 | 768 | 0.48 | Why? |
| Diabetes Mellitus | 4 | 2018 | 8207 | 0.47 | Why? |
| Coronary Artery Bypass | 1 | 2018 | 629 | 0.46 | Why? |
| Interleukin-1beta | 1 | 2017 | 992 | 0.45 | Why? |
| Intracranial Hemorrhages | 1 | 2020 | 1170 | 0.45 | Why? |
| Checklist | 1 | 2017 | 714 | 0.44 | Why? |
| Dyslipidemias | 1 | 2018 | 791 | 0.43 | Why? |
| Coronary Disease | 2 | 2016 | 645 | 0.43 | Why? |
| Health Services Research | 1 | 2017 | 756 | 0.43 | Why? |
| Risk Factors | 28 | 2021 | 71621 | 0.43 | Why? |
| Hemorrhage | 10 | 2021 | 3013 | 0.43 | Why? |
| Percutaneous Coronary Intervention | 6 | 2018 | 3646 | 0.41 | Why? |
| Informed Consent | 1 | 2017 | 890 | 0.41 | Why? |
| Hospital Mortality | 7 | 2021 | 22087 | 0.39 | Why? |
| Coronary Artery Disease | 3 | 2018 | 2570 | 0.38 | Why? |
| Factor Xa Inhibitors | 3 | 2018 | 490 | 0.36 | Why? |
| Patient Readmission | 1 | 2018 | 1543 | 0.36 | Why? |
| Surgical Procedures, Operative | 4 | 2018 | 2662 | 0.36 | Why? |
| Thrombophilia | 1 | 2020 | 1935 | 0.35 | Why? |
| C-Reactive Protein | 2 | 2021 | 7972 | 0.34 | Why? |
| Biomarkers | 7 | 2021 | 23361 | 0.34 | Why? |
| Ischemia | 4 | 2019 | 901 | 0.34 | Why? |
| Pyrroles | 1 | 2020 | 292 | 0.33 | Why? |
| Blood Coagulation | 1 | 2020 | 2768 | 0.33 | Why? |
| Patient Safety | 3 | 2018 | 4885 | 0.32 | Why? |
| Lipoprotein(a) | 2 | 2017 | 92 | 0.32 | Why? |
| Databases, Factual | 3 | 2020 | 6248 | 0.32 | Why? |
| Medication Therapy Management | 1 | 2020 | 312 | 0.32 | Why? |
| Aged | 39 | 2021 | 215776 | 0.32 | Why? |
| Drug Administration Schedule | 2 | 2018 | 2324 | 0.32 | Why? |
| Purinergic P2Y Receptor Antagonists | 2 | 2018 | 206 | 0.32 | Why? |
| Therapeutic Irrigation | 1 | 2017 | 167 | 0.31 | Why? |
| Middle Aged | 38 | 2021 | 270681 | 0.31 | Why? |
| Deep Sedation | 1 | 2017 | 121 | 0.31 | Why? |
| Hyperglycemia | 1 | 2017 | 1363 | 0.30 | Why? |
| Risk Assessment | 10 | 2021 | 25439 | 0.30 | Why? |
| Diabetes Complications | 1 | 2018 | 2358 | 0.30 | Why? |
| Female | 47 | 2021 | 380317 | 0.29 | Why? |
| Male | 45 | 2021 | 367725 | 0.29 | Why? |
| Hospitalization | 10 | 2021 | 54280 | 0.29 | Why? |
| Warfarin | 3 | 2018 | 402 | 0.29 | Why? |
| Thrombin | 2 | 2018 | 325 | 0.28 | Why? |
| Acute Coronary Syndrome | 1 | 2018 | 2107 | 0.28 | Why? |
| Quality Improvement | 1 | 2017 | 2435 | 0.27 | Why? |
| Humans | 70 | 2021 | 930598 | 0.27 | Why? |
| Antithrombins | 2 | 2018 | 353 | 0.27 | Why? |
| Occupational Health | 1 | 2020 | 3965 | 0.27 | Why? |
| Piperidines | 1 | 2020 | 795 | 0.26 | Why? |
| Odds Ratio | 4 | 2021 | 5861 | 0.26 | Why? |
| Education, Medical, Undergraduate | 1 | 2017 | 1392 | 0.26 | Why? |
| Heart Diseases | 1 | 2020 | 3503 | 0.25 | Why? |
| Atrial Fibrillation | 4 | 2018 | 2320 | 0.25 | Why? |
| Renal Insufficiency, Chronic | 1 | 2018 | 2654 | 0.25 | Why? |
| Decision Making | 1 | 2017 | 3132 | 0.25 | Why? |
| Respiratory Insufficiency | 2 | 2020 | 7301 | 0.24 | Why? |
| Pyrimidines | 1 | 2020 | 1557 | 0.23 | Why? |
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 5002 | 0.23 | Why? |
| Research Design | 2 | 2018 | 5830 | 0.22 | Why? |
| Disease Progression | 1 | 2020 | 13580 | 0.22 | Why? |
| Thromboxane B2 | 1 | 2020 | 23 | 0.22 | Why? |
| Endovascular Procedures | 3 | 2019 | 1302 | 0.21 | Why? |
| Sodium Chloride Symporter Inhibitors | 1 | 2020 | 45 | 0.21 | Why? |
| Critical Illness | 3 | 2021 | 17281 | 0.21 | Why? |
| Colitis, Ulcerative | 1 | 2020 | 1037 | 0.21 | Why? |
| CD40 Antigens | 1 | 2020 | 118 | 0.20 | Why? |
| Hypertension | 3 | 2020 | 8895 | 0.20 | Why? |
| United States | 12 | 2020 | 46150 | 0.20 | Why? |
| Respiratory Tract Infections | 1 | 2020 | 6817 | 0.20 | Why? |
| Cyclooxygenase 1 | 1 | 2018 | 20 | 0.20 | Why? |
| Integrin beta3 | 1 | 2019 | 35 | 0.20 | Why? |
| Disease Management | 1 | 2018 | 6841 | 0.19 | Why? |
| Thromboxane A2 | 1 | 2018 | 17 | 0.19 | Why? |
| Pneumonia, Viral | 8 | 2020 | 243684 | 0.19 | Why? |
| Myocardial Revascularization | 2 | 2019 | 267 | 0.19 | Why? |
| Receptors, Purinergic P2Y12 | 1 | 2018 | 42 | 0.19 | Why? |
| Adenosine Diphosphate | 1 | 2018 | 63 | 0.19 | Why? |
| Receptor, PAR-1 | 1 | 2018 | 24 | 0.19 | Why? |
| Cultural Competency | 1 | 2019 | 125 | 0.19 | Why? |
| Retrospective Studies | 17 | 2021 | 105322 | 0.19 | Why? |
| Adult | 18 | 2021 | 244371 | 0.18 | Why? |
| Heparin | 2 | 2021 | 2600 | 0.18 | Why? |
| Vitamin K | 2 | 2017 | 263 | 0.18 | Why? |
| Platelet Adhesiveness | 1 | 2017 | 19 | 0.17 | Why? |
| Vena Cava, Inferior | 1 | 2018 | 103 | 0.17 | Why? |
| Thrombocytosis | 1 | 2017 | 21 | 0.17 | Why? |
| Recommended Dietary Allowances | 1 | 2017 | 43 | 0.17 | Why? |
| Aged, 80 and over | 11 | 2020 | 88759 | 0.17 | Why? |
| Home Nursing | 1 | 2018 | 62 | 0.17 | Why? |
| Reference Values | 1 | 2020 | 795 | 0.17 | Why? |
| Students, Medical | 1 | 2017 | 4032 | 0.17 | Why? |
| Ultrasonography, Doppler, Duplex | 1 | 2018 | 168 | 0.16 | Why? |
| Obesity | 1 | 2018 | 7388 | 0.16 | Why? |
| Cellular Reprogramming | 1 | 2018 | 117 | 0.16 | Why? |
| Calgranulin A | 1 | 2017 | 74 | 0.16 | Why? |
| Multivariate Analysis | 2 | 2019 | 5440 | 0.16 | Why? |
| Coronavirus Infections | 7 | 2020 | 253789 | 0.16 | Why? |
| Calcium Channel Blockers | 1 | 2020 | 367 | 0.16 | Why? |
| Phenotype | 2 | 2019 | 4037 | 0.16 | Why? |
| New York City | 2 | 2020 | 7432 | 0.16 | Why? |
| Thrombolytic Therapy | 2 | 2018 | 2218 | 0.16 | Why? |
| Heart Defects, Congenital | 2 | 2018 | 933 | 0.16 | Why? |
| Adrenergic beta-Antagonists | 1 | 2020 | 465 | 0.16 | Why? |
| Cell Adhesion | 1 | 2017 | 230 | 0.16 | Why? |
| Prevalence | 4 | 2020 | 25773 | 0.15 | Why? |
| Lipopolysaccharide Receptors | 1 | 2019 | 357 | 0.15 | Why? |
| Smoking Prevention | 1 | 2017 | 116 | 0.15 | Why? |
| Professionalism | 1 | 2018 | 171 | 0.15 | Why? |
| Platelet Function Tests | 1 | 2017 | 231 | 0.15 | Why? |
| Receptors, Interleukin-1 | 1 | 2017 | 161 | 0.15 | Why? |
| Time Factors | 6 | 2020 | 31397 | 0.15 | Why? |
| Diabetes Mellitus, Experimental | 1 | 2017 | 192 | 0.14 | Why? |
| Kidney Function Tests | 1 | 2017 | 520 | 0.14 | Why? |
| Intraoperative Complications | 1 | 2017 | 221 | 0.14 | Why? |
| Hospitals, Urban | 1 | 2020 | 950 | 0.14 | Why? |
| Carotid Arteries | 1 | 2016 | 182 | 0.14 | Why? |
| Life Style | 2 | 2018 | 2708 | 0.14 | Why? |
| Ethics Committees, Research | 1 | 2017 | 272 | 0.14 | Why? |
| Hemoglobins | 1 | 2020 | 958 | 0.14 | Why? |
| Treatment Outcome | 12 | 2020 | 51732 | 0.14 | Why? |
| Administration, Oral | 2 | 2018 | 2340 | 0.14 | Why? |
| Platelet Count | 1 | 2020 | 1381 | 0.13 | Why? |
| Stents | 2 | 2018 | 916 | 0.13 | Why? |
| Gene Expression Regulation | 2 | 2017 | 4020 | 0.13 | Why? |
| Chi-Square Distribution | 1 | 2017 | 961 | 0.13 | Why? |
| Walking | 1 | 2018 | 442 | 0.13 | Why? |
| Quality Assurance, Health Care | 1 | 2018 | 596 | 0.13 | Why? |
| Double-Blind Method | 3 | 2019 | 5988 | 0.13 | Why? |
| Pyridones | 1 | 2018 | 738 | 0.12 | Why? |
| Cerebral Hemorrhage | 1 | 2020 | 820 | 0.12 | Why? |
| Denmark | 5 | 2018 | 2654 | 0.12 | Why? |
| Troponin I | 1 | 2021 | 1298 | 0.12 | Why? |
| Colonoscopy | 2 | 2020 | 738 | 0.12 | Why? |
| Mindfulness | 1 | 2018 | 437 | 0.12 | Why? |
| Office Visits | 1 | 2017 | 489 | 0.12 | Why? |
| Registries | 5 | 2018 | 12327 | 0.11 | Why? |
| Drug Utilization | 1 | 2017 | 619 | 0.11 | Why? |
| Natriuretic Peptide, Brain | 1 | 2019 | 1215 | 0.11 | Why? |
| Renal Insufficiency | 1 | 2018 | 810 | 0.11 | Why? |
| Hemostasis | 1 | 2018 | 811 | 0.11 | Why? |
| Myocardial Ischemia | 1 | 2018 | 781 | 0.11 | Why? |
| Protective Factors | 1 | 2017 | 1720 | 0.11 | Why? |
| Troponin | 1 | 2017 | 1058 | 0.11 | Why? |
| Wearable Electronic Devices | 1 | 2018 | 694 | 0.11 | Why? |
| Heart | 1 | 2020 | 1791 | 0.11 | Why? |
| Cardiac Catheterization | 1 | 2018 | 882 | 0.10 | Why? |
| Fellowships and Scholarships | 1 | 2018 | 931 | 0.10 | Why? |
| Vascular Diseases | 1 | 2018 | 846 | 0.10 | Why? |
| Drug Therapy, Combination | 3 | 2018 | 7268 | 0.10 | Why? |
| NF-kappa B | 1 | 2017 | 1301 | 0.10 | Why? |
| Comorbidity | 4 | 2021 | 34796 | 0.10 | Why? |
| Physicians | 2 | 2019 | 4214 | 0.10 | Why? |
| Cardiotonic Agents | 1 | 2012 | 418 | 0.10 | Why? |
| Exercise Therapy | 1 | 2018 | 976 | 0.09 | Why? |
| Postoperative Complications | 2 | 2018 | 5861 | 0.09 | Why? |
| Vascular Surgical Procedures | 1 | 2017 | 882 | 0.09 | Why? |
| Cause of Death | 2 | 2020 | 4823 | 0.09 | Why? |
| Educational Measurement | 1 | 2017 | 930 | 0.09 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.09 | Why? |
| Smoking Cessation | 1 | 2017 | 826 | 0.09 | Why? |
| Stroke Volume | 1 | 2019 | 2153 | 0.09 | Why? |
| Cerebrovascular Disorders | 1 | 2017 | 1040 | 0.09 | Why? |
| Coronary Angiography | 1 | 2018 | 2275 | 0.09 | Why? |
| Gastrointestinal Contents | 1 | 2017 | 7 | 0.09 | Why? |
| Acute Disease | 2 | 2019 | 6029 | 0.09 | Why? |
| Lymphocyte Count | 1 | 2020 | 4758 | 0.09 | Why? |
| Flow Cytometry | 1 | 2017 | 2393 | 0.09 | Why? |
| Laxatives | 1 | 2017 | 18 | 0.09 | Why? |
| Pyrazoles | 1 | 2018 | 1791 | 0.09 | Why? |
| Diabetes Mellitus, Type 2 | 2 | 2018 | 6166 | 0.08 | Why? |
| Prognosis | 4 | 2019 | 32490 | 0.08 | Why? |
| Pandemics | 8 | 2020 | 389249 | 0.08 | Why? |
| Thromboembolism | 1 | 2020 | 2101 | 0.08 | Why? |
| Prospective Studies | 4 | 2018 | 43301 | 0.08 | Why? |
| Perioperative Care | 1 | 2018 | 1329 | 0.08 | Why? |
| Thrombectomy | 1 | 2018 | 2272 | 0.08 | Why? |
| Stomach | 1 | 2017 | 141 | 0.08 | Why? |
| Bariatric Surgery | 1 | 2017 | 1298 | 0.08 | Why? |
| Obesity, Morbid | 1 | 2017 | 1340 | 0.08 | Why? |
| Patient Care | 1 | 2018 | 1664 | 0.08 | Why? |
| Amputation | 2 | 2019 | 331 | 0.08 | Why? |
| Health Surveys | 1 | 2018 | 2841 | 0.08 | Why? |
| Logistic Models | 2 | 2021 | 9089 | 0.08 | Why? |
| Diagnosis, Differential | 1 | 2020 | 7220 | 0.08 | Why? |
| Pilot Projects | 1 | 2018 | 5182 | 0.08 | Why? |
| Macrophages | 1 | 2018 | 2784 | 0.07 | Why? |
| Hypoglycemic Agents | 1 | 2018 | 2165 | 0.07 | Why? |
| Cells, Cultured | 1 | 2017 | 5835 | 0.07 | Why? |
| Cross-Sectional Studies | 3 | 2018 | 53120 | 0.07 | Why? |
| Gene Expression Profiling | 1 | 2017 | 3788 | 0.07 | Why? |
| Follow-Up Studies | 3 | 2019 | 17020 | 0.07 | Why? |
| Adolescent | 3 | 2021 | 86841 | 0.07 | Why? |
| Propofol | 1 | 2017 | 172 | 0.07 | Why? |
| Social Determinants of Health | 1 | 2017 | 1757 | 0.07 | Why? |
| Feeding Behavior | 1 | 2017 | 1909 | 0.07 | Why? |
| Clinical Competence | 1 | 2019 | 3263 | 0.07 | Why? |
| Young Adult | 4 | 2020 | 93724 | 0.07 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2020 | 5277 | 0.07 | Why? |
| Guideline Adherence | 1 | 2017 | 2309 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2020 | 3892 | 0.06 | Why? |
| Hydrogen-Ion Concentration | 1 | 2017 | 993 | 0.06 | Why? |
| Smoking | 1 | 2017 | 3358 | 0.06 | Why? |
| Cohort Studies | 4 | 2020 | 36005 | 0.06 | Why? |
| Venous Thrombosis | 1 | 2018 | 2739 | 0.06 | Why? |
| Patient Acuity | 1 | 2020 | 1755 | 0.06 | Why? |
| Kidney | 1 | 2017 | 3648 | 0.06 | Why? |
| Communicable Diseases | 1 | 2018 | 2148 | 0.06 | Why? |
| Polyethylene Glycols | 1 | 2017 | 574 | 0.06 | Why? |
| Cardiology | 1 | 2018 | 2873 | 0.06 | Why? |
| Severity of Illness Index | 3 | 2020 | 48226 | 0.06 | Why? |
| Burnout, Professional | 1 | 2018 | 2489 | 0.06 | Why? |
| Aging | 1 | 2018 | 3581 | 0.06 | Why? |
| Reproducibility of Results | 1 | 2019 | 11304 | 0.06 | Why? |
| Quality of Health Care | 1 | 2004 | 1948 | 0.06 | Why? |
| Predictive Value of Tests | 1 | 2017 | 9537 | 0.06 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.06 | Why? |
| New York | 2 | 2020 | 2488 | 0.05 | Why? |
| Neutrophils | 1 | 2017 | 5476 | 0.05 | Why? |
| Sex Factors | 1 | 2018 | 11014 | 0.05 | Why? |
| Cardiac Surgical Procedures | 1 | 2004 | 1931 | 0.05 | Why? |
| Protein Kinase Inhibitors | 1 | 2020 | 1585 | 0.05 | Why? |
| Ultrasonography | 1 | 2016 | 4409 | 0.05 | Why? |
| Propensity Score | 2 | 2020 | 2690 | 0.05 | Why? |
| Signal Transduction | 1 | 2017 | 7207 | 0.05 | Why? |
| Case-Control Studies | 1 | 2019 | 17671 | 0.05 | Why? |
| Communication | 1 | 2017 | 5206 | 0.05 | Why? |
| Phlebography | 1 | 2018 | 65 | 0.05 | Why? |
| Popliteal Artery | 1 | 2018 | 32 | 0.05 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.05 | Why? |
| Vascular Patency | 1 | 2018 | 96 | 0.05 | Why? |
| Endarterectomy | 1 | 2018 | 60 | 0.05 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.05 | Why? |
| Mice, Obese | 1 | 2017 | 29 | 0.04 | Why? |
| Actigraphy | 1 | 2018 | 102 | 0.04 | Why? |
| Premenopause | 1 | 2017 | 63 | 0.04 | Why? |
| Recurrence | 2 | 2018 | 3675 | 0.04 | Why? |
| Limb Salvage | 1 | 2017 | 124 | 0.04 | Why? |
| Vena Cava Filters | 1 | 2018 | 89 | 0.04 | Why? |
| Heart Failure | 1 | 2019 | 6638 | 0.04 | Why? |
| Job Application | 1 | 2019 | 186 | 0.04 | Why? |
| Anesthesia | 1 | 2017 | 1236 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Accreditation | 1 | 2018 | 203 | 0.04 | Why? |
| Femoral Artery | 1 | 2018 | 213 | 0.04 | Why? |
| Age Factors | 1 | 2018 | 21039 | 0.04 | Why? |
| Ticlopidine | 1 | 2017 | 193 | 0.04 | Why? |
| Endoscopy | 1 | 2017 | 1564 | 0.04 | Why? |
| Symptom Assessment | 1 | 2020 | 4967 | 0.04 | Why? |
| Meditation | 1 | 2018 | 140 | 0.04 | Why? |
| Inflammation | 1 | 2019 | 13255 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.04 | Why? |
| District of Columbia | 1 | 2017 | 343 | 0.04 | Why? |
| Social Welfare | 1 | 2017 | 141 | 0.04 | Why? |
| Blood Vessel Prosthesis Implantation | 1 | 2018 | 226 | 0.04 | Why? |
| Postoperative Period | 1 | 2017 | 651 | 0.04 | Why? |
| Treatment Failure | 1 | 2021 | 2106 | 0.04 | Why? |
| Organizational Culture | 1 | 2018 | 395 | 0.04 | Why? |
| Stress, Psychological | 1 | 2018 | 10231 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.03 | Why? |
| Career Choice | 1 | 2019 | 498 | 0.03 | Why? |
| Adenosine | 1 | 2017 | 509 | 0.03 | Why? |
| Neuroimaging | 1 | 2020 | 1106 | 0.03 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2021 | 1731 | 0.03 | Why? |
| Mice, Knockout | 1 | 2017 | 1815 | 0.03 | Why? |
| Weight Loss | 1 | 2017 | 826 | 0.03 | Why? |
| Morbidity | 1 | 2017 | 1426 | 0.03 | Why? |
| Bayes Theorem | 1 | 2020 | 3237 | 0.03 | Why? |
| Interviews as Topic | 1 | 2019 | 1952 | 0.03 | Why? |
| Antibodies, Neutralizing | 1 | 2017 | 25288 | 0.02 | Why? |
| Telephone | 1 | 2018 | 1705 | 0.02 | Why? |
| Computed Tomography Angiography | 1 | 2018 | 2153 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Patient Compliance | 1 | 2018 | 1468 | 0.02 | Why? |
| Congresses as Topic | 1 | 2018 | 1347 | 0.02 | Why? |
| Antihypertensive Agents | 1 | 2020 | 1962 | 0.02 | Why? |
| Survival Analysis | 1 | 2021 | 7592 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2017 | 5542 | 0.02 | Why? |
| Sleep | 1 | 2018 | 2695 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Poverty | 1 | 2017 | 2302 | 0.02 | Why? |
| Cities | 1 | 2017 | 4937 | 0.02 | Why? |
| ROC Curve | 1 | 2017 | 6024 | 0.02 | Why? |
| Renin-Angiotensin System | 1 | 2020 | 3661 | 0.02 | Why? |
| Health Care Surveys | 1 | 2004 | 2942 | 0.02 | Why? |
| Social Support | 1 | 2018 | 3183 | 0.02 | Why? |
| Incidence | 2 | 2017 | 25622 | 0.02 | Why? |
| Survival Rate | 1 | 2017 | 9206 | 0.01 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 1510 | 0.01 | Why? |
| Surveys and Questionnaires | 2 | 2018 | 43792 | 0.01 | Why? |
| Length of Stay | 1 | 2017 | 11042 | 0.01 | Why? |
| Healthcare Disparities | 1 | 2017 | 3893 | 0.01 | Why? |
| Practice Patterns, Physicians' | 1 | 2017 | 4927 | 0.01 | Why? |
| Attitude of Health Personnel | 1 | 2017 | 4741 | 0.01 | Why? |
| Child | 1 | 2018 | 70012 | 0.01 | Why? |
| Animals | 1 | 2017 | 78931 | 0.01 | Why? |
| Telemedicine | 1 | 2018 | 25032 | 0.00 | Why? |